BNP Paribas Financial Markets’s Immune Design Corp. IMDZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-7,127
Closed -$41.7K 4661
2019
Q1
$41.7K Buy
7,127
+4,883
+218% +$16.6K ﹤0.01% 3607
2018
Q4
$2.92K Buy
2,244
+1,654
+280% +$2.87K ﹤0.01% 3730
2018
Q3
$2.04K Sell
590
-3
-0.5% -$11 ﹤0.01% 4254
2018
Q2
$2.7K Sell
593
-5,520
-90% -$22K ﹤0.01% 4220
2018
Q1
$20.2K Sell
6,113
-2,714
-31% -$9.61K ﹤0.01% 3922
2017
Q4
$34.4K Buy
8,827
+7,350
+498% +$40K ﹤0.01% 3832
2017
Q3
$15.3K Sell
1,477
-98
-6% -$964 ﹤0.01% 3731
2017
Q2
$15.4K Buy
1,575
+1,286
+445% +$9.02K ﹤0.01% 3798
2017
Q1
$1.97K Sell
289
-523
-64% -$3.02K ﹤0.01% 3545
2016
Q4
$4.47K Buy
812
+58
+8% +$410 ﹤0.01% 3748
2016
Q3
$5.71K Buy
754
+318
+73% +$2.33K ﹤0.01% 3361
2016
Q2
$3.56K Buy
436
+384
+738% +$4.79K ﹤0.01% 3381
2016
Q1
$676 Sell
52
-2,158
-98% -$24.9K ﹤0.01% 2540
2015
Q4
$44.4K Sell
2,210
-337
-13% -$5.81K ﹤0.01% 2891
2015
Q3
$31.1K Buy
2,547
+1,606
+171% +$30.1K ﹤0.01% 3150
2015
Q2
$19.4K Buy
941
+799
+563% +$18.9K ﹤0.01% 3066
2015
Q1
$3K Buy
+142
New +$3.71K ﹤0.01% 3384

BNP Paribas Financial Markets's IMDZ Position: Q2 2019 in Review

BNP Paribas Financial Markets sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 7,127 shares — an estimated $41.7K sold.

BNP Paribas Financial Markets first reported a position in IMDZ in Q1 2015 and held it in 17 quarters. The position peaked at $44.4K in Q4 2015. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.

  • BNP Paribas Financial Markets reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 7,127 Immune Design Corp. shares in Q2 2019, an estimated $41.7K.
  • BNP Paribas Financial Markets first reported a position in Immune Design Corp. in Q1 2015 and held it in 17 quarters.
  • BNP Paribas Financial Markets's Immune Design Corp. position peaked at $44.4K in Q4 2015.
  • 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2019, filed 30 Jul 2019.